GlassScriptPhysician profile
Kalpesh S Amin
NPI 1003911645
$4,317.18
in general payments reported to CMS, 2019-2025
21 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $576 · 2021: $1,158 · 2022: $389 · 2023: $829 · 2024: $565 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.92 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $738.24 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $481.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $411.68 | 2019-2025 | Farxiga |
| Medtronic, INC. | $395.56 | 2023 | Cobalt Dr Mri Surescan, Capsurefix Novus Mri Surescan, Linq II |
| Abbott Laboratories | $260.94 | 2021-2024 | Gallant |
| Pfizer INC. | $251.65 | 2019-2020 | |
| Boston Scientific Corporation | $208.59 | 2022-2024 | Watchman Flx |
| Mannkind Corporation | $202.94 | 2023 | Afrezza, V-Go |
| Actelion Pharmaceuticals US, INC. | $174.98 | 2024-2025 | Uptravi, Opsumit |
| Lilly USA, LLC | $165.29 | 2022-2023 | Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.04 | 2019-2023 | Lifevest |
| Novo Nordisk INC | $146.97 | 2019-2024 | Ozempic, Rybelsus |
| Cequr Corporation | $144.60 | 2023-2024 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $125.05 | 2024 | Gvoke Hypopen |
| Amgen INC. | $124.97 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $118.42 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.98 | 2022 | |
| Amarin Pharma, INC. | $44.63 | 2019 | |
| Merck Sharp & Dohme LLC | $32.22 | 2020-2023 | Verquvo |
| Redhill Biopharma INC. | $23.00 | 2020 | |
| Renalytix Ai, INC. | $17.89 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalpesh Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.